OpGen to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022
January 18 2022 - 7:30AM
OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company
harnessing the power of molecular diagnostics and informatics to
help combat infectious disease, announced today it is participating
in Edison Group’s Open House Event, scheduled to take place
virtually this month.
The three-day event, in association with London Stock Exchange,
global law firm Taylor Wessing and OpenExchange, will take place
between 25th-27th January, focusing on 33 companies. Day one will
feature businesses within pharmaceuticals & drug discovery, day
two focuses on AI & technology in healthcare, while businesses
adopting new approaches to hard-to-solve problems will round off
the event.
Content will be available to stream from January 25th on
Edison’s website and OpenExchange.tv. Attendance is free and anyone
wanting to attend can sign up here:
https://www.edisongroup.com/event/edison-open-house-global-healthcare-2022/
For more information on the event and details on how to
register, please see below.
Edison Group:Global Healthcare Open House
Conference 2022Date: January 25-27th, 2022Edison Group Open House
Registration
Presentation information: The company
presentation will be available on demand on www.edisongroup.com
beginning at 7am ET on Thursday, January 27th. The presentation
will also be available on OpGen’s investor relations page.
1x1 Meeting Registration: To register for a 1x1
meetings with Company, please visit this link.
For any questions about the event or how to register, please
reach out to openhouse@edisongroup.com
About OpGen, Inc.
OpGen, Inc. (Rockville, MD, USA) is a precision
medicine company harnessing the power of molecular diagnostics and
bioinformatics to help combat infectious disease. Along with our
subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are
developing and commercializing molecular microbiology solutions
helping to guide clinicians with more rapid and actionable
information about life threatening infections to improve patient
outcomes, and decrease the spread of infections caused by
multidrug-resistant microorganisms, or MDROs. OpGen’s product
portfolio includes Unyvero®, Acuitas® AMR Gene Panel and the ARES
Technology Platform including ARESdb®, using NGS technology and
AI-powered bioinformatics solutions for antibiotic response
prediction.
For more information, please visit
www.opgen.com.
About Edison Group:
Edison’s leading research and investor relations consultancy
connects listed companies to the widest pool of global investors.
By focusing on both the volume and quality of investors reached –
across institutions, family offices, wealth managers and retail
investors, Edison can create and gauge intent to purchase, even in
the darkest pools of capital. www.edisongroup.com
OpGen:Oliver SchachtPresident and
CEOInvestorRelations@opgen.com
OpGen Press Contact:Matthew
Bretzius FischTank Marketing and PR
matt@fischtankpr.com
OpGen Investor Contact:Maxwell
ColbertEdison
Group mcolbert@edisongroup.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jul 2023 to Jul 2024